Progesterone Receptor (PGR) content of breast cancer tissue is an
important parameter in the prediction of prognosis and response to endocrine
therapy. PGR clone 16 is directed against the human progesterone receptor
molecule. A prokaryotic recombinant protein, corresponding to the N-terminal
region of the A form of human progesterone receptor, was used as the immunogen.
Antibody characterization studies demonstrated that PGR Clone 16 reacts with
both A and B forms of human progesterone receptor in Western blotting
procedure.